PMID: 3759224Oct 1, 1986Paper

Antihypertensive and metabolic effects of diltiazem and nifedipine

Hypertension
K L SchulteR Gotzen

Abstract

The antihypertensive effect of diltiazem (180-270 mg/day) and nifedipine (40-60 mg/day) in slow-release forms was assessed over 8 weeks in a double-blind parallel study in 40 subjects with essential hypertension at rest and during exercise. Blood pressure was comparably reduced in both groups at rest as well as during exercise. The responder rates (greater than or equal to 10% reduction in diastolic blood pressure) after 8 weeks of therapy were 53% at rest and 75% during exercise in the diltiazem group and 78% and 50%, respectively, in the nifedipine group. Diltiazem decreased heart rate by 8% (p less than 0.01), while nifedipine did not affect it. As a consequence, myocardial oxygen consumption, as judged by the pressure-rate product, was reduced by diltiazem. Resting plasma norepinephrine levels were increased significantly after 8 weeks of diltiazem therapy. Plasma epinephrine, renin, aldosterone, glucose, insulin, and lactate and routine laboratory parameters were unchanged at the end of the study. No significant changes in total cholesterol and triglyceride levels were observed after 8 weeks. Whereas therapy with diltiazem resulted in an 8% fall in low density lipoprotein cholesterol after 8 weeks (p less than 0.05), nifed...Continue Reading

References

May 21, 1979·European Journal of Clinical Pharmacology·O L PedersenE B Pedersen
Nov 1, 1974·The Journal of Clinical Endocrinology and Metabolism·W OelkersA Blümel
Jun 1, 1974·Archives of Internal Medicine·J Koch-Weser
Sep 11, 1970·Deutsche medizinische Wochenschrift·W D BrittingerM Strauch
Jan 1, 1984·Journal of Cardiovascular Pharmacology·B N Trost, P Weidmann
Jan 1, 1983·European Journal of Clinical Pharmacology·S Dean, M J Kendall
Jan 1, 1982·Journal of Cardiovascular Pharmacology·K MidtbøJ van der Meer
Nov 1, 1983·Journal of Cardiovascular Pharmacology·L HallinL Hansson
Dec 1, 1980·The American Journal of Cardiology·P D Henry
Jun 1, 1984·The American Journal of Cardiology·I K InouyeD Loge
Jul 7, 1984·British Medical Journal·S K BhatnagarA R Al-Yusuf
Aug 1, 1983·Journal of Hypertension·P Lund-Johansen, P Omvik
Jul 4, 1981·British Medical Journal·S CharlesA E Lambert
Dec 1, 1981·Naunyn-Schmiedeberg's Archives of Pharmacology·H M Thiede, W Kehr
May 1, 1983·British Journal of Clinical Pharmacology·C G SempleA R Lorimer
Jan 1, 1980·Current Medical Research and Opinion·T Donnelly, A D Harrower
Nov 1, 1980·European Journal of Clinical Pharmacology·D GiuglianoM Varricchio
Jan 1, 1982·European Journal of Clinical Pharmacology·R Eggertsen, L Hansson
Jan 1, 1960·Physiological Reviews·E D FREIS

❮ Previous
Next ❯

Citations

Mar 1, 1995·Journal of Clinical Pharmacology·M R Weir
Dec 14, 1987·The American Journal of Cardiology·D R Abernethy, S C Montamat
Aug 1, 1996·The American Journal of the Medical Sciences·E C MaduT D Fraker
Mar 1, 1991·The American Journal of Medicine·K O'MalleyE O'Brien
Jun 15, 1988·The American Journal of Cardiology·O B Holland, P E Pool
Oct 1, 1989·International Journal of Cardiology·B Maharaj
Oct 24, 1998·Endocrinology and Metabolism Clinics of North America·W T DonahooR H Eckel
Oct 5, 1988·The American Journal of Cardiology·P E PoolR R Evans
May 1, 1993·Journal of the American College of Cardiology·R A ChahineS K Vanov
Mar 1, 1988·Hypertension·R P Russell
Jul 1, 1997·Hypertension·W B StasonT C Chalmers
May 16, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jin WangLingzhong Meng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.